psoriatic arthritis
Conditions
Interventions
1:Methotrexate 7.5mg-15mg qw po
2:secukinumab 150mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
Sponsors
Peking Union Medical Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Complies with the 2006 CASPAR PsA classification standard; Plan to continue using UPA or MTX treatment for at least 3 months in the future; • Have not used any DMARDs medication before screening; • Stop csDMARDs and traditional Chinese patent medicines and simple preparations 4 weeks before screening, and stop bDMARDs 12 weeks before screening • If subjects take Nonsteroidal anti-inflammatory drug and/or glucocorticoids orally, the NSAIDs dosage must be stable at least 2 weeks before screening • Disease is active (DAPSA>14 points) Sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1)Complicated with other inflammatory arthritis or systemic autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.); 2)Allergies to the intended drug (UPA or MTX); 3)Pregnant or expectant women; 4)Complicated with active infections or malignant tumors; 5)Anti-osteoporosis drugs are being used (bisphosphonate, dinomimab, romozumab, Teriparatide, Calcitonin); 6)Primary osteoporosis before diagnosis of PsA; 7)Other situations where the researcher deems it inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bone erosion ; | — |
Secondary
| Measure | Time frame |
|---|---|
| volumetric bone density ; | — |
Countries
China
Contacts
Public ContactLin Qiao
Peking Union Medical Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed